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The Malaria Box, assembled by the Medicines for Malaria Venture, is a set of 400 structurally diverse,
commercially available compounds with demonstrated activity against blood-stage Plasmodium falcip-
arum. The compounds are a representative subset of the 20,000 in vitro antimalarials identiﬁed from the
high-throughput screening efforts of St. Jude Children's Research Hospital (TN, USA), Novartis and
GlaxoSmithKline. In addition, a small set of active compounds from commercially available libraries was
added to this group, but it has not previously been published. Elucidation of the biochemical pathways
on which these compounds act is a major challenge; therefore, access to these compounds has been
made available free of charge to the investigator community. Here, the Malaria Box compounds were
tested for activity against the formation of b-hematin, a synthetic form of the heme detoxiﬁcation bio-
mineral, hemozoin. Further, the mechanism of action of these compounds within the malaria parasite
was explored. Ten of the Malaria Box compounds demonstrated signiﬁcant inhibition of b-hematin
formation. In this assay, doseeresponse data revealed IC50 values ranging from 8.7 to 22.7 mM for these
hits, each of which is more potent than chloroquine (a known inhibitor of hemozoin formation). The
in vitro antimalarial activity of these ten hits was conﬁrmed in cultures of the chloroquine sensitive D6
strain of the parasite resulting in IC50 values of 135e2165 nM, followed by testing in the multidrug
resistant strain, C235. Cultures of P. falciparum (D6) were then examined for their heme distribution
following treatment with nine of the commercially available conﬁrmed compounds, seven of which
disrupted the hemozoin pathway.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction Research Hospital, Novartis and GlaxoSmithKline (GSK) to screenIt has been over ﬁfty years since resistance to chloroquine (CQ)
in Plasmodium falciparum was ﬁrst reported, and since then the
malaria parasite continues to rapidly develop resistance to current
replacement therapeutics, including sulfadoxine-pyrimethamine
and artemisinin combination therapies (Abdul-Ghani et al., 2013;
Ashley et al., 2014; Wongsrichanalai et al., 2002). While pharma-
ceutical companies have lacked interest in developing new drugs
for malaria, the advent of public-private partnerships (PPP's) has
facilitated collaborative efforts between pharmaceutical companies
with non-proﬁt organizations and universities (Nwaka and Ridley,
2003). An exemplar PPP, Medicines for Malaria Venture (MMV),
was established in 1999 to enable the discovery of new, effective
and affordable antimalarial drugs. Notably, MMV supported the
high-throughput screening (HTS) efforts of St. Jude Children's.Y. Fong), rdsandlin@mgh.
du (D.W. Wright).
ipt.
r Ltd on behalf of Australian Socieover 4 million compounds for in vitro antimalarial activity
(Guiguemde et al., 2010; Plouffe et al., 2008; Gamo et al., 2010). Of
these, over 20,000 compounds have been identiﬁed with potent
in vitro antimalarial activity. Perhaps the most impressive aspect of
this collaborative discovery effort is that the structures of these
chemical starting points have been deposited in the ChEMBL
neglected tropical diseases archive, an Open Access screening re-
pository that allows researchers from around the world to access
this data free of charge (https://www.ebi.ac.uk/chemblntd). To
encourage the broader investigation of these compounds, MMV
announced free access to the compounds of the Malaria Box e a set
of 400 compounds selected from the 20,000 hits that are repre-
sentative of the breadth of chemical diversity and predicted to be
pharmacologically valid. While these compounds are potent in vitro
antimalarials, all possible drug targets have not been explored. In
this report, the Malaria Box compounds have been tested for
inhibitory activity against the formation of b-hematin, the synthetic
form of the heme-detoxiﬁcation biomineral, hemozoin, followed by
target validation in a parasite culture.
During the intraerythrocytic stage of the life cycle, the malaria
parasite catabolizes host hemoglobin as its primary source ofty for Parasitology. This is an open access article under the CC BY license (http://
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vacuole, an acidic organelle (pH ~4.8) (Hayward et al., 2006). Dur-
ing the process of hemoglobin degradation, toxic free heme is
released. Lacking the enzyme heme oxygenase used for heme-
detoxiﬁcation by most organisms, the parasite coverts the free
heme into a non-toxic, insoluble crystal called hemozoin. Since the
parasite catabolizes up to 80% of the erythrocyte's hemoglobin
content, local concentrations of free heme could potentially reach
200e500 mM if hemozoin crystallization did not occur (Scholar
and Pratt, 2000).
Hemozoin formation is mediated by neutral lipid bodies
concentrated within the digestive food vacuole that serve as a
reservoir for free heme (Hoang et al., 2010b; Pisciotta et al., 2007).
These lipids were extracted from the parasite and shown to consist
of a speciﬁc blend of mono- and di-acylglycerols (Pisciotta et al.,
2007). Synthetic neutral lipid droplets (SNLDs) composed of the
biologically relevant blend of neutral lipids were shown to be a
kinetically competent site for the in vitro formation of b-hematin,
with a crystallization half-life of <5 min (Hoang et al., 2010a,
2010b). In addition to accumulation of free heme within the
SNLDs, molecular dynamic simulations have demonstrated that the
lipophilic environment of the lipid body would serve to stabilize
the hemozoin precursor dimer and that formation of hemozoin
would be favored at the lipid/aqueous interface (de Villiers et al.,
2007). These observations would suggest that inhibitors of hemo-
zoin formation would interact with free heme either at the lipid/
aqueous interface or within the neutral lipid body.
One of the most successful antimalarial ever developed, CQ, acts
by inhibiting the formation of hemozoin (Egan et al., 1994; Sullivan
et al., 1996). However, the parasite has developed resistance to
certain quinoline antimalarials as a result of mutations in Pf CQ
resistant transporter (PfCRT), a membrane protein localized to the
digestive food vacuole (Fidock et al., 2000). These mutations reduce
the concentrations of CQ within the digestive food vacuole, acting
as an efﬂux pump, thereby lowering the vacuolar CQ concentration
and preventing the interactions with its target, heme/hemozoin.
However, since resistance is not the result of changes in the
pathway of hemozoin formation itself, this biomineralization pro-
cess remains a valid drug target.
Recently, an HTS assay for b-hematin formation was developed
(Carter et al., 2010) and utilized in a screen of 144,330 compounds
(Sandlin et al., 2014). This assay utilized a low-cost, lipophilic
micelle-forming detergent (Nonidet P-40) to mimic the neutral
lipid bodies present within the digestive food vacuole. Within this
screen there were 530 hits identiﬁed, and remarkably, 32% of the
hits were also active in in vitro cultures of P. falciparum, inhibiting
90% parasitemia.Wright and coworkers argued that this retention
of biological activity is due to the use of a biologically relevant
mediator of crystallization, thus the in vitro b-hematin inhibition
assay more closely recapitulates the chemistry of the digestive food
vacuole. In these studies, the Malaria Box compounds were tested
in the b-hematin formation assay to detect inhibitors of this crys-
tallization process. Of the 400 tested, ten compounds were iden-
tiﬁed to have doseeresponse b-hematin inhibitory activity more
potent than that of CQ.
While these compounds were shown to possess antimalarial
and in vitro b-hematin inhibition activity, this drug target pathway
must be validated within a parasite culture through an assay
developed by Egan and coworkers (Combrinck et al., 2013). Within
P. falciparum iron (III) protoporphyrin IX can be observed in three
forms: hemoglobin, free heme, and hemozoin. Egan and coworkers
showed that a dose response treatment of CQ, a known hemozoin
inhibitor, resulted in a rise in free heme and a decline in hemozoin
levels. In contrast, pyrimethamine, an antimalarial known to target
folate biosynthesis without affecting hemozoin formation, resultedin a steady baseline level of free heme, while still causing parasite
death. Quantiﬁcation of these three heme species following a dose
response treatment can be used to conﬁrm the biological pathway
targeted in culture. The nine commercially available b-hematin
inhibitors found were subsequently examined for their levels of
free heme and -seven were conﬁrmed to act against this particular
pathway in culture.
2. Materials and methods
2.1. Malaria Box compounds
The Malaria Box library of 400 compounds was provided by the
MMV at a concentration of 10 mM in dimethyl sulfoxide (DMSO) in
384-well microtiter plates. Due to the small quantities of com-
pound delivered in the Malaria Box, the additional testing was
conducted using compounds purchased from ChemBridge and
ChemDiv. While MMV666689 was identiﬁed as a potent b-hematin
inhibitor in the screen, it did not undergo the additional testing due
to lack of commercial availability.
2.2. b-Hematin formation assay
As previously described by Sandlin et al., 20 mL of water was
added to clear 384-well ﬂat bottommicrotiter plates containing the
Malaria Box compounds. Five microliters of 348 mM Nonidet P-40
detergent (NP-40, Shell Chemical Co. originated from Pierce
Biotechnology, Rockford, IL) was added to each well to mediate the
formation of b-hematin, followed by the addition of 7 mL of acetone
to prevent heme precipitation. A 25 mM stock was prepared by
dissolving hemin chloride in DMSO followed by one minute of
sonication and ﬁltration through a 0.22 mm PVDF membrane ﬁlter
unit. A 228 mM hematin suspension was then prepared from the
hemin stock in 2 M acetate buffer (pH 4.8). Twenty-ﬁve microliters
of this hematin suspension was added to the plate before incu-
bating for six hours in a shaking water bath at 37 C (Sandlin et al.,
2014). The assay was analyzed using the pyridine-ferrochrome
method (Ncokazi and Egan, 2005). A solution of 50% pyridine,
20% acetone, water, and 200 mM HEPES buffer (pH 7.4) was added
to each well (the ﬁnal concentration of pyridine was 5% v/v). The
plate was then put on a shaker for ten minutes. The absorbance of
the resulting complexwasmeasured at 405 nm on a BioTek Synergy
H4 plate reader.
2.3. Identiﬁcation of b-hematin inhibitors
A 125 nL volume of each Malaria Box compound (10 mM) was
acoustically delivered to a 384-well plate using a Labcyte Echo 550
liquid handler. Duplicate plates were prepared and the ﬁnal con-
centration of compound was ~22 mM, near the IC50 of amodiaquine
(AQ) (a known antimalarial b-hematin inhibitor) in this assay.
Potentiator (IC100 of AQ) and vehicle (DMSO only, 0.22%) controls
were added in an alternating checkerboard pattern to the ﬁrst two
and last two columns of each plate. The reagents described above
for the b-hematin formation assay were added to each plate and
incubated. Following addition of the pyridine solution, the per-
centage of free heme in each test well was determined relative to
the positive and negative control wells. Any Malaria Box compound
that inhibited >50% b-hematin formation was considered a hit.
2.4. Concentration response curves
Concentration response curves were determined for each hit
using the b-hematin formation assay. A concentration range of
Fig. 1. Identiﬁcation of Malaria Box b-hematin inhibitors in the screen. The b-hematin
formation assay identiﬁed ten potent inhibitors from the 400 Malaria Box compounds
screened. The absorbance of test compounds is represented by green squares. The solid
lines at 0.6 (blue) and 3.8 (red) represent the negative and positive controls, respec-
tively, while the dashed lines represent three standard deviations of the respective
control. The solid black line at 2.2 is the 50% inhibitory cutoff. Compounds above the
50% inhibitory threshold were considered hits. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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generated using GraphPad Prism v5.0 (March 7, 2007).
2.5. Malaria SYBR green 1-based ﬂuorescence (MSF) assay
The P. falciparum strain D6 (Walter Reed Army Institute of
Research [WRAIR]/Sierra Leone) was cultured using an adapted
method by Trager and Jensen (Trager and Jensen, 1976). Inhibitors
of b-hematin formation were tested in this CQ-sensitive strain of
P. falciparum using a previously published method (Johnson et al.,
2007) with modiﬁcations (Sandlin et al., 2014). Initial dos-
eeresponse curves were established by testing compound con-
centrations from 0.03 to 23 mMwith a ﬁnal DMSO concentration of
0.25%. To ensure that DMSO did not interfere with parasite growth,
a control plate was used containing wells with 0.25% DMSO and
wells containing no DMSO. Concentration response curves were
generated using GraphPad Prism v5.0. Subsequent testing with the
hit compounds from this initial screen was done on both D6 and a
multidrug-resistant strain of P. falciparum (C235, WRAIR). Dose
response curveswere conducted using the commercially purchased
compounds with duplicate measurements.
2.6. Heme speciation assay
The heme speciation assay was conducted using a method
previously described (Combrinck et al., 2013). A P. falciparum (D6)
culture was sorbitol synchronized at the early ring stage before
being evenly divided among 25 cm2 culture ﬂasks and treated with
the test compound at 0, 0.5, 1, and 2 times the IC50 value previously
determined in the MSF assay. The cultures were then incubated at
37 C and 5% O2, 5% CO2, 90% N2 until the late trophozoite stage was
reached (~32 h). At this time, saponin (0.05% ﬁnal concentration)
was used to selectively lyse the erythrocytes, leaving the tropho-
zoites intact. The parasites were then lysed following a freeze-
ethaw cycle. The hemoglobin fraction present in the parasite was
collected as the supernatant following the addition of 0.02M HEPES
buffer (pH 7.4), 4% sodium dodecyl sulfate, and centrifugation.
Pyridine was added to the resulting pellet to solubilize the free
heme. The remaining substance consisted of hemozoin, which was
solubilized by the addition of 0.1 M sodium hydroxide. The absor-
bance peak maximum at 405 nm was collected to quantify the
percentages of each heme species (Pf hemoglobin, intercellular free
heme, and hemozoin) present in each trophozoite culture. Parasite
morphology was observed through microscopy analysis and
percent survival was determined by SYBR Green I ﬂuorescence.
2.7. Vacuolar accumulation ratio (VAR) and lipid accumulation
ratio (LAR)
Vacuolar Accumulation Ratios (VARs) were calculated using the
method of Krogstad and Lipid Accumulation Ratio (LAR) values
were calculated using the model of Warhurst (Krogstad and
Schlesinger, 1986; Warhurst et al., 2007). Here, a cytosol pH of 7.4
and vacuolar pH of 4.8 were used with the pKa values generated by
Marvin ChemAxon software to calculate VAR values. For LAR, logD
values at a pH of 7.4 were also calculated with this software.
3. Results
The Malaria Box compounds were screened for inhibitory ac-
tivity with the b-hematin formation assay (Fig. 1). Ten hits were
identiﬁed that inhibited >50% of crystallization relative to the IC100
of AQ and DMSO vehicle controls. Subsequent doseeresponse data
indicated that the hits were very potent, with activities from 8.7 to
22.7 mM (the IC50 concentrations of AQ and CQ in this assay are21.0 mM and 48.7 mM, respectively). In order to conﬁrm that the
integrity of the Malaria Box compounds received had not been
compromised, the hits were tested in in vitro cultures of the CQ-
sensitive D6 strain and multidrug-resistant C235 strain of
P. falciparum (Table 1). The values obtained ranged from 135 to
2165 nM and 156e3469 nM, respectively, which are comparable to
values reported by ChEMBL against the CQ-sensitive 3D7 strain.
The vacuolar accumulation ratio (VAR) is measured based on the
pH difference between the cytosol (7.4) and the digestive food
vacuole (4.8) in the parasite. The lipid accumulation ratio (LAR) is
the ratio of drug found within the neutral lipid bodies of the
digestive vacuole, the location of hemozoin formation. Calculated
VARs and LARs for CQ (Table 2) are consistent with previously re-
ported values and correlate with their b-hematin inhibitory activ-
ities (Warhurst et al., 2007). While the Malaria Box hit compounds
do not possess similarly high VAR values, their LAR values indicate
accumulation in lipophilic environments, explaining their high
activity against this particular pathway. It is suggested that pos-
sessing high LAR values is especially important for activity against
resistant parasite strains due to the lipophilic character of the drugs
interacting with the hydrophobic channel of PfCRT (Warhurst et al.,
2007). This is evident with the resistance index values calculated
(RI¼ IC50 of resistant strain (C235)/IC50 of sensitive strain (D6)). The
relatively low RI values indicate these compounds are fairly potent
against resistant strains, a vital component to novel antimalarials.
The Malaria Box compounds identiﬁed in the HTS assay are
reﬂective of previously reported b-hematin scaffolds described in
the literature (Fig. 2). Benzimidazoles were recognized as a potent
inhibitor of b-hematin formation byWright and coworkers (Sandlin
et al., 2014) and likewise, three hits from the current study
(MMV007384, MMV011895, and MMV666607) fall into this
chemical scaffold. In another screen for b-hematin inhibition,
Camacho et al. incorporated a nitrofuran into several benzimid-
azole-based structures and found efﬁcacy on par with that of CQ
(Camacho et al., 2011). In addition to this scaffold targeting the
hemozoin pathway, these compounds have also been reported as
potent antimalarials in both CQ-sensitive and CQ-resistant parasite
strains. This is ideal in a novel antimalarial as P. falciparum drug
resistance has quickly become widespread, causing major public
health concerns. Therefore, if a compound is found active against
Table 1
Ten compounds from the Malaria Box identiﬁed to inhibit b-hematin formation and have antimalarial activity against P. falciparum. 50% inhibitory concentrations are listed
against b-hematin inhibition, a CQ-sensitive strain (D6), and a multidrug-resistant strain (C235), along with target validation results with the heme speciation assay. CQ and
pyrimethamine results are included as a positive and negative control, respectively, for known antimalarials.
Structure MMV identiﬁer b-hematin IC50 (mM) D6 IC50 MSF assay (nM) C235 IC50 MSF assay (nM) RI D Free heme (%)
MMV007384 10.6 ± 2.6 2165 ± 151a 3469 ± 24a 1.6 18
MMV666607 22.7 ± 1.5 260 ± 23 458 ± 28 1.8 21
MMV665799 16.0 ± 2.3 1639 ± 23 2765 ± 34 1.7 49
MMV665888 13.1 ± 2.5 1410 ± 47 1305 ± 98 0.9 28
MMV006767 14.8 ± 1.7 782 ± 35 1564 ± 77 2 35
MMV007273 8.7 ± 2.1 262 ± 62 351 ± 2 1.3 21
MMV000753 14.0 ± 4.9 1212 ± 4 1609 ± 77 1.3 21
MMV020750 9.1 ± 2.1 366 ± 15 466 ± 22 1.3 0
MMV011895 12.2 ± 2.0 135 ± 4 156 ± 6 1.2 0
MMV666689 15.6 ± 2.5 465b NT NA NT
MMV009063 Not Active 610 ± 81 856 ± 84 1.4 0
Chloroquine 48.7 ± 2.7 14 ± 1 48 ± 4 3.4 21
Pyrimethamine Not Active 12 ± 2 NT NA 0
NA ¼ Not applicable, NT ¼ Not tested.
a Average mean and standard deviation of two replicates from commercially purchased compounds.
b Value from a single measurement, compound provided by MMV.
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round of testing.
The quinoline scaffold (MMV006767) was also identiﬁed in our
screen of the Malaria Box compounds. Quinolines are perhaps the
most well known and investigated b-hematin inhibiting scaffolds
due to the potent activity of the quinoline derivative, CQ, against
sensitive strains of P. falciparum (Ncokazi and Egan, 2005; Rush
et al., 2009). Even with the widespread drug resistance against
CQ, quinolines remain an effective scaffold since the mechanism of
resistance is due to a gene mutation in PfCRT and is unrelated to the
mechanism of action (Sinha et al., 2014). Furthermore, it was found
that drug resistance is compound speciﬁc, allowing quinoline de-
rivatives to still be potential drug candidates (Ridley et al., 1996).Two benzamide analogues (MMV665799 and MMV665888)
were also identiﬁed as b-hematin inhibitors in the Malaria Box. In
previous screens, similar benzamide compounds have been re-
ported as inhibitors of b-hematin formation (Guiguemde et al.,
2010; Sandlin et al., 2014). Furthermore, treatment with select
benzamides have been shown to exhibit large intracellular free
heme levels compared to other scaffolds, which can begin to pro-
vide insight into their exact mechanism of inhibiting hemozoin
formation (Sandlin et al., 2014).
The triarylimidazole scaffold (MMV000753, MMV007273, and
MMV020750) has been previously identiﬁed in the results of only
one other b-hematin activity high-throughput screen (Sandlin
et al., 2014). The remaining hit compound from this screen,
Table 2
Calculated vacuolar accumulation ratio (VAR) and lipid accumulation ratio (LAR) values of the ten identiﬁed hit compounds.
Structure MMV identiﬁer Vacuolar Accumulation
ratio
Lipid Accumulation
ratio
Structure MMV identiﬁer Vacuolar Accumulation
ratio
Lipid Accumulation
ratio
MMV007384 25 1.6  106 MMV007273 2 9.1  106
MMV666607 10 4.8  103 MMV000753 6 2.5  109
MMV665799 7 2.4  103 MMV020750 2 5.9  104
MMV665888 NA 1.0  105 MMV011895 38 5.8  105
MMV006767 5 2.1  103 MMV666689 1 1.1  106
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some activity against late-stage gametocytes (Sun et al., 2014).
The nine commercially available compounds underwent target
validationwithin a culture of P. falciparum (D6) (Table 1). Following
a dose response treatment of the b-hematin inhibitors, the changesFig. 2. Main scaffolds identiﬁed as b-hematin inhibitors. Four scaffolds identiﬁedin the distribution of iron (III) protoporphyrin IX was observed
within Pf hemoglobin, free heme, and hemozoin. Seven of the nine
antimalarial b-hematin inhibitors tested were found to perturb the
hemozoin formation pathway in a parasite culture. This was shown
through a signiﬁcant (p < 0.05) increase in free heme levels fromin the Malaria Box collection and their representative b-hematin inhibitors.
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survival (Fig. 3). Parasite morphology by microscopy analysis
conﬁrmed that the control culture was indeed collected as late
trophozoites. Increasing concentrations of drug treatment resulted
in altered parasite morphology, demonstrating visually that they
were no longer viable (Supplementary Figure 1). MMV009063 was
shown to have in vitro antimalarial activity (IC50 ¼ 610 ± 81 nM),
but did not inhibit b-hematin formation. Therefore in addition to
pyrimethamine (a non-hemozoin inhibitor) (Supplementary
Figure 2), this compound was used as a negative control for
target validation. A culture treated in a dose response manner with
MMV009063 resulted in decreased parasite viability, while the free
heme levels remained unchanged from basal levels, indicating it is
acting upon a biological pathway other than hemozoin formation.
By observing the distribution of iron (III) protoporphyrin IX
following drug treatment, we can now focus on these hits that have
been validated as hemozoin inhibitors in culture.
4. Discussion
Currently, most antimalarials only treat the blood stage of the
parasite life cycle, as this is where it is most pathogenic resulting in
febrile symptoms. However, if this disease is going to be eradicated,
then treatmentmust also target the asymptomatic stages, including
the liver and sexual stages in both drug sensitive and resistant
strains (Delves et al., 2012). Recently, combination therapies have
been used to combat challenges with drug resistance. This strategy
could also allow for drugs to target separate pathways, which will
increase its efﬁcacy and help prevent recrudescence (Vathsala et al.,
2012). Thus, both target based and phenotypic screening can nar-
row the focus towards wholly efﬁcacious lead compounds.
The Malaria Box is the ﬁrst open access library of compounds
offered free of charge to the malaria research community. There are
several advantages to the development of this library. Most
importantly, open access to the Malaria Box increases the avail-
ability of these compounds to the malaria research community,
which will facilitate target-elucidation. The process of target-
elucidation is expensive and time-consuming, but is necessary in
order to synthetically increase the afﬁnity of the lead compound forFig. 3. Target validation of hit compounds by comparing heme distribution following treatm
inhibitor, MMV007384 (A) and a non-inhibitor, MMV009063 (B). Both compounds were foun
assay and their dose response curves are shown. Statistical signiﬁcance was calculated usinits target. Since the Malaria Box is a reasonably manageable sam-
pling of high-priority compounds, laboratories with expertise of
speciﬁc biochemical pathways can quickly identify compounds that
act on that target. In our screen for b-hematin inhibitors, we
observed high potency within four scaffolds, consisting of ten hits.
4.1. Benzimidazoles
The most promising compound found in our screen of the Ma-
laria Box set of compounds was MMV007384 as it was validated to
be a b-hematin inhibitor and additionally reported active in both
the asexual and sexual stages of the intraerythrocytic life cycle. This
benzimidazole was reported to be a potent inhibitor of both early-
and late-stage gametocytes, making it a more ideal malaria drug
candidate (Duffy and Avery, 2013; Lucantoni et al., 2013; Bowman
et al., 2014; Sun et al., 2014).
Another compound within this scaffold (MMV666607) is
structurally similar to ﬁve of the MMV benzimidazoles in the study
by Bowman et al. (MMV000248, MMV000444, MMV000445,
MMV007384, MMV396723, MMV665902) as they each contain a
guanidine moiety. However, they found that the structural re-
quirements for gametocyticidal activity are rather strict, in that four
of the ﬁve mentioned benzimidazole compounds didn't possess
gametocytocidal activity despite some containing a secondary
alcohol on the linker or similar tertiary amine moieties.
MMV000248, MMV011895, and MMV666607 each contain activity
against early- and late-stage gametocytes; (Lucantoni et al., 2013;
Sun et al., 2014; Duffy and Avery, 2013) therefore, this scaffold
space should still be explored further for its potential to target
multiple stages of the parasite life cycle.
Benzimidazoles have also been screened against the pyrimidine
biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), but
were found to have low potency (IC50 > 27 mM) and low selectivity
between the parasite and human enzyme (Heikkila et al., 2007).
The difference in activity levels between the two targets indicates
that this class of compounds is more likely to affect a single asexual
biochemical pathway in vivo. However, the concept of one drug
targeting two pathways is of interest in the development of com-
bination therapies.ent. Distribution of heme species following treatment with a Malaria Box b-hematin
d to have activity against D6 P. falciparum in the MSF SYBR Green I Fluorescence based
g a two-tailed unpaired t-test with p < 0.05.
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In a recent screen with the Malaria Box collection for activity
against gametocytes, quinoline compounds were found to be more
potent against early-stage gametocytes compared to the asexual
stage (Lucantoni et al., 2013). MMV665782 and MMV020500
exhibited a 9- and 7-fold reduced activity against the asexual stage
of the 3D7 strain compared to early-stage gametocytes of the NF54
strain. However, these two speciﬁc Malaria Box compounds
showed less than 20% inhibition of b-hematin formation in the
present screen. In the search for a novel antimalarial, the most
promising candidates include those that target the parasite in both
the sexual and asexual stages.
4.3. Benzamides
The benzamide scaffold has also been shown to have inhibitory
activity against P. falciparum DHODH (Heikkila et al., 2007). A
common theme amongst the most potent members within this
class of compounds is the presence of a halogenated substituent in
the para position of the aniline moiety. Such substitutions play a
role in CQ, as the chlorine, when placed in the 7 position, reportedly
increases the binding afﬁnity of the molecule to the hemozoin
precursor (Vippagunta et al., 1999) as well as improve anti-
plasmodial activity overall (Lavrado et al., 2010).
4.4. Triaryl imidazoles
TheMMVMalaria Box compoundswere screened for early-stage
gametocytocidal activity using a luciferase-based assay (Lucantoni
et al., 2013). Two of the triaryl imidazole b-hematin inhibitors
(MMV007273 and MMV000753) also contained activity against
NF54 early-stage gametocytes with IC50 values of 1.361 and
0.627 mM, respectively. This scaffold should be pursued further as
imidazoles have been found in many biologically active compounds
including antimicrobial, antitumoral, and antiprotozoal (Rani et al.,
2013).
4.5. Conclusions
In the search for a novel antimalarial, it is promising that these
scaffolds contribute to multiple drug target pathways within
P. falciparum. Due to the increasing drug resistance, a successful
treatment will consist of a combination therapy, where each drug
would target a distinct mechanism. This method of treatment is
being used with artemisinin-based combination therapies, which
are currently the most effective antimalarial medicine (WHO).
Discovering a single compound that could simultaneously inhibit
two biological mechanisms could decrease the cost and allow for a
simpler treatment plan overall. Using combination therapies, such
as a hemozoin inhibitor with an antifolate, will help prevent further
development of resistance.
Reported here is the ﬁrst published b-hematin inhibition spe-
ciﬁc data for the Malaria Box collection. Ten potent inhibitors of b-
hematin formation have been identiﬁed from these compounds
distributed by MMV, with seven of the nine commercially available
having been validated for targeting the hemozoin formation
pathway, resulting in an overall hit rate of 1.75%. The high valida-
tion rate indicates that the conditions of our in vitro b-hematin
inhibition assay better represents the parasite environment of
hemozoin formation as compared to other high-throughput b-he-
matin screens that only observed a hit rate of 0.1% (Rush et al.,
2009). These seven inhibitors will undergo additional testing to
determine pharmacokinetics of each compound and those withacceptable properties will continue on for testing of in vivo efﬁcacy
in the Plasmodium berghei mouse model.
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